Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$9.17 - $19.29 $213,101 - $448,280
-23,239 Reduced 67.17%
11,358 $125,000
Q1 2023

May 12, 2023

SELL
$12.53 - $21.71 $102,946 - $178,369
-8,216 Reduced 19.19%
34,597 $464,000
Q4 2022

Feb 10, 2023

BUY
$11.61 - $16.11 $497,058 - $689,717
42,813 New
42,813 $529,000
Q4 2020

Feb 08, 2021

SELL
$24.48 - $42.47 $1.66 Million - $2.87 Million
-67,609 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$39.09 - $53.44 $332,186 - $454,133
-8,498 Reduced 11.17%
67,609 $2.77 Million
Q2 2020

Aug 17, 2020

BUY
$46.7 - $92.04 $3.31 Million - $6.53 Million
70,962 Added 1379.24%
76,107 $3.61 Million
Q2 2020

Aug 11, 2020

BUY
$46.7 - $92.04 $15,177 - $29,913
325 Added 6.74%
5,145 $531,000
Q1 2020

May 14, 2020

SELL
$48.35 - $118.68 $231,113 - $567,290
-4,780 Reduced 49.79%
4,820 $279,000
Q4 2019

Feb 06, 2020

BUY
$57.36 - $124.1 $51,796 - $112,062
903 Added 10.38%
9,600 $1.19 Million
Q3 2019

Nov 12, 2019

BUY
$58.69 - $80.46 $128,648 - $176,368
2,192 Added 33.7%
8,697 $552,000
Q2 2019

Aug 14, 2019

BUY
$77.77 - $120.68 $233,310 - $362,040
3,000 Added 85.59%
6,505 $497,000
Q1 2019

May 15, 2019

BUY
$91.83 - $120.68 $278,336 - $365,781
3,031 Added 639.45%
3,505 $370,000
Q4 2018

Feb 13, 2019

BUY
$85.79 - $126.46 $26,423 - $38,949
308 Added 185.54%
474 $40,000
Q3 2018

Nov 08, 2018

SELL
$88.49 - $127.55 $51,324 - $73,979
-580 Reduced 77.75%
166 $20,000
Q2 2018

Aug 03, 2018

BUY
$60.0 - $85.67 $4,320 - $6,168
72 Added 10.68%
746 $63,000
Q1 2018

May 11, 2018

BUY
$52.72 - $67.25 $4,797 - $6,119
91 Added 15.61%
674 $41,000
Q4 2017

Feb 08, 2018

SELL
$58.2 - $72.76 $4,947 - $6,184
-85 Reduced 12.72%
583 $34,000
Q3 2017

Nov 06, 2017

BUY
$57.01 - $118.75 $38,082 - $79,325
668
668 $39,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.